Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel were named Life Sciences Stars in the Hatch-Waxman Patent Litigation Practice Area by LMG Life Sciences in its 2019 guide.
Intellectual Property Practice Group Co-Leader Imron Aly has joined the advisory board for the Center for Biosimilars, an online resource for emerging pharmaceutical biotechnology that discusses the current landscape for advanced health care management with top industry thought leaders.
Schiff Hardin LLP is proud to announce that the firm and three of its attorneys have been ranked in the eighth edition of IAM Patent 1000: The World’s Leading Patent Professionals.
Schiff Hardin is pleased to announce that the firm has been ranked as ‘Recommended’ by Managing Intellectual Property magazine in the Illinois IP Stars Patent Contentious category, which includes dispute resolution work, litigation and enforcement, as well as Hatch-Waxman, International Trade Commission, and multinational litigation work.
Schiff Hardin successfully secured a favorable outcome for our client, Fresenius Kabi USALLC, in a patent-infringement suit filed by Hospira Inc., which paves the way for Fresenius to market a new generic drug.
Joel Wallace was quoted on a recent ruling from Federal Judge Reed O’Connor in the Federal District Court in Fort Worth, Texas, that the Affordable Care Act’s (ACA) individual coverage mandate is unconstitutional and, in the absence of the individual mandate, the rest of the ACA cannot stand.
In the quick pound of a gavel, the entire U.S. pharmaceutical and biologics industries were thrown into doubt after Judge Reed O’Connor of the United States District Court for the Northern District of Texas found the individual mandate of the Affordable Care Act (ACA) – and therefore the entire act – unconstitutional.
Intellectual Property Practice Group Co-Leader Imron Aly was quoted on how including patents in the U.S. Food and Drug Administration’s “Purple Book” — which lists biological products, including any biosimilar and interchangeable biological products — might affect developers.
Intellectual Property Practice Group Co-Leader Imron Aly described the three key features of the U.S. Food and Drug Administration’s Biosimilar Action Plan: education, interchangeability, and international data sharing.
Hatch-Waxman and Biosimilars Practice Group Leader Imron Aly was quoted on why patients in the United States may have to wait longer than those in the European Union for the biosimilar adalimumab, referencing the brand name drug, Humira.
Intellectual Property Practice Group Co-Leader Imron Aly spoke with The Center for Biosimilars on key takeaways from the long-running case Saint Regis Mohawk Tribe, Allergan v. Mylan
Imron Aly and Sailesh Patel have been named Life Sciences Stars in the Hatch-Waxman Patent Litigation Practice Area by LMG Life Sciences in its 2018 guide.
Intellectual Property Group Co-Leader Imron Aly represented Alkem Laboratories Ltd. as part of a group of generic drug makers urging a Federal Circuit panel to nix patents for the tapentadol opioid painkiller Nucynta, marketed by Depomed (now Assertio). IP Law360 reported on the oral argument.
Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel were featured in Leading Lawyers Magazine—2018 Business Edition for their successful track record in challenging giant pharmaceutical companies to bring generic drugs to the marketplace.